X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS GSK PHARMA DR. DATSONS LABS/
GSK PHARMA
 
P/E (TTM) x -10.9 67.5 - View Chart
P/BV x 0.2 13.6 1.2% View Chart
Dividend Yield % 0.0 2.1 -  

Financials

 DR. DATSONS LABS   GSK PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
GSK PHARMA
Mar-18
DR. DATSONS LABS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1262,760 4.6%   
Low Rs312,040 1.5%   
Sales per share (Unadj.) Rs133.0339.0 39.2%  
Earnings per share (Unadj.) Rs0.241.4 0.4%  
Cash flow per share (Unadj.) Rs6.645.9 14.4%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs128.8242.9 53.0%  
Shares outstanding (eoy) m31.6684.70 37.4%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.67.1 8.3%   
Avg P/E ratio x516.157.9 890.7%  
P/CF ratio (eoy) x11.852.3 22.6%  
Price / Book Value ratio x0.69.9 6.1%  
Dividend payout %084.5 0.0%   
Avg Mkt Cap Rs m2,477203,280 1.2%   
No. of employees `000NANA-   
Total wages/salary Rs m565,234 1.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m4,21128,715 14.7%  
Other income Rs m79545 14.4%   
Total revenues Rs m4,28929,260 14.7%   
Gross profit Rs m5695,059 11.2%  
Depreciation Rs m204380 53.8%   
Interest Rs m4302 21,510.0%   
Profit before tax Rs m135,222 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m61,892 0.3%   
Profit after tax Rs m53,508 0.1%  
Gross profit margin %13.517.6 76.7%  
Effective tax rate %48.036.2 132.6%   
Net profit margin %0.112.2 0.9%  
BALANCE SHEET DATA
Current assets Rs m6,85221,815 31.4%   
Current liabilities Rs m6,71115,999 41.9%   
Net working cap to sales %3.320.3 16.5%  
Current ratio x1.01.4 74.9%  
Inventory Days Days16164 253.0%  
Debtors Days Days31819 1,704.4%  
Net fixed assets Rs m3,67312,475 29.4%   
Share capital Rs m317847 37.4%   
"Free" reserves Rs m3,76119,726 19.1%   
Net worth Rs m4,07820,573 19.8%   
Long term debt Rs m1,6716 27,846.7%   
Total assets Rs m12,63339,475 32.0%  
Interest coverage x1.02,612.0 0.0%   
Debt to equity ratio x0.40 140,502.2%  
Sales to assets ratio x0.30.7 45.8%   
Return on assets %3.48.9 38.7%  
Return on equity %0.117.1 0.7%  
Return on capital %7.726.2 29.2%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m964564 170.9%   
Fx outflow Rs m6077,429 8.2%   
Net fx Rs m357-6,865 -5.2%   
CASH FLOW
From Operations Rs m1,3454,728 28.4%  
From Investments Rs m-2,256-1,042 216.5%  
From Financial Activity Rs m-1,200-3,066 39.1%  
Net Cashflow Rs m-2,111620 -340.6%  

Share Holding

Indian Promoters % 4.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 1.4 23.8 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 15.4 611.0%  
Shareholders   20,807 102,036 20.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   JUBILANT LIFE SCIENCES  PLETHICO PHARMA  WOCKHARDT LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS